Helius Medical Technologies, Inc. provided revenue guidance for the first quarter of 2022. For the period, the company expects revenue to range from $150,000 to $170,000 and quarterly revenue to increase sequentially each quarter throughout the year as the U.S. commercialization of PoNS develops.
Helius Medical Technologies, Inc.
Equities
HSDT
US42328V8019
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.843 USD | +0.96% |
|
-8.94% | -89.51% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-89.51% | 2.5M | |
+3.26% | 209B | |
+6.55% | 183B | |
+31.66% | 158B | |
+34.32% | 114B | |
+5.13% | 67.29B | |
+19.33% | 54.83B | |
-3.30% | 46.88B | |
-4.84% | 38.58B | |
+3.83% | 36.65B |
- Stock Market
- Equities
- HSDT Stock
- News Helius Medical Technologies, Inc.
- Helius Medical Technologies, Inc. Provides Revenue Guidance for the First Quarter of 2022